Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Some studies sponsored by Novo Nordisk suggest that semaglutide may actually help reduce the risk of kidney disease over the ... including worsening chronic kidney failure, especially if ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.